skip to content
Health economic evaluation of primary prevention strategies against cardiovascular disease Preview this item
ClosePreview this item
Checking...

Health economic evaluation of primary prevention strategies against cardiovascular disease

Author: Torbjørn WisløffOle Frithjof NorheimSigrun HalvorsenRandi SelmerIvar Sønbø KristiansenAll authors
Publisher: Oslo : Norwegian Knowledge Centre for the Health Services, December 2008.
Series: Online access: NCBI NCBI Bookshelf.
Edition/Format:   eBook : Document : English
Summary:
Background Cardiovascular disease (CVD) has for decades been the most common cause of death in Norway and most other Western countries. Several groups of drugs have shown in clinical trials to prevent CVD. In this report, we have evaluated the cost-effectiveness of these drugs. Methods Based on a model of the progression of CVD from healthy to death, we explored which drugs that might be cost-effective. Analyses  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Systematic Review
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Torbjørn Wisløff; Ole Frithjof Norheim; Sigrun Halvorsen; Randi Selmer; Ivar Sønbø Kristiansen; Nasjonalt kunnskapssenter for helsetjenesten,
OCLC Number: 1048107392
Notes: English summary excerpted from full report in Norwegian: Kostnader og leveårsgevinster ved medikamentell primærforebygging av hjertekarsykdom.
Excerpt from Systematic reviews no. 34-2008.
Description: 1 online resource (1 PDF file (pages 5-7))
Series Title: Online access: NCBI NCBI Bookshelf.
Responsibility: Torbjørn Wisløff, Ole Frithjof Norheim, Sigrun Halvorsen, Randi M. Selmer, Ivar Sønbø Kristiansen.

Abstract:

Background Cardiovascular disease (CVD) has for decades been the most common cause of death in Norway and most other Western countries. Several groups of drugs have shown in clinical trials to prevent CVD. In this report, we have evaluated the cost-effectiveness of these drugs. Methods Based on a model of the progression of CVD from healthy to death, we explored which drugs that might be cost-effective. Analyses were conducted both compared to no treatment and between different drugs. Analyses were conducted on different risk levels and in different age groups for both men and women. We also performed probabilistic sensitivity analyses. Our analyses were accompanied by a systematic review of other economic evaluations of preventive strategies against CVD. Results Calcium channel blockers, thiazides, beta blockers, aspirin and statins were all cost-effective compared to no treatment for all groups of men and women in age groups between 40 and 69. The life year gains for each of the drugs varied between 3 and 17 months. Calcium channel blockers and thiazides were the most cost-effective combination of two antihypertensive drugs. In the base case analyses, the combination of calcium channel blockers, thiazides and ACE-inhibitors was the most cost-effective combination of three drugs. The sensitivity analyses indicate considerable uncertainty related to the question of which was the most cost-effective of the antihypertensive drugs. Whether treatment was cost-effective compared to no treatment was concerned with less uncertainty. Our systematic review of other economic evaluations showed considerable discrepancies between analyses of prevention strategies against CVD. Discussion The results of this study indicate that statins, several antihypertensives and aspirin are cost-effective in all analysed groups between 40 and 69 years old. It is worthwhile noting, however, that the model is built on numerous assumptions, and this introduces considerable uncertainty with respect to optimal choice of therapies.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1048107392> # Health economic evaluation of primary prevention strategies against cardiovascular disease
    a schema:MediaObject, schema:Book, schema:CreativeWork ;
    library:oclcnum "1048107392" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/no> ;
    rdfs:seeAlso <http://experiment.worldcat.org/entity/work/data/5375679156#CreativeWork/kostnader_og_levearsgevinster_ved_medikamentell_primaerforebygging_av_hjertekarsykdom> ; # Kostnader og leveårsgevinster ved medikamentell primærforebygging av hjertekarsykdom.
    schema:about <http://experiment.worldcat.org/entity/work/data/5375679156#Topic/cardiovascular_agents_therapeutic_use> ; # Cardiovascular Agents--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/5375679156#Topic/cardiovascular_diseases_drug_therapy> ; # Cardiovascular Diseases--drug therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/5375679156#Topic/cost_benefit_analysis> ; # Cost-Benefit Analysis
    schema:about <http://experiment.worldcat.org/entity/work/data/5375679156#Topic/cardiovascular_agents_economics> ; # Cardiovascular Agents--economics
    schema:author <http://experiment.worldcat.org/entity/work/data/5375679156#Person/wisloff_torbjorn> ; # Torbjørn Wisløff
    schema:author <http://experiment.worldcat.org/entity/work/data/5375679156#Person/kristiansen_ivar_sonbo_1947> ; # Ivar Sønbø Kristiansen
    schema:author <http://experiment.worldcat.org/entity/work/data/5375679156#Person/selmer_randi> ; # Randi Selmer
    schema:author <http://experiment.worldcat.org/entity/work/data/5375679156#Person/halvorsen_sigrun> ; # Sigrun Halvorsen
    schema:author <http://experiment.worldcat.org/entity/work/data/5375679156#Person/norheim_ole_frithjof> ; # Ole Frithjof Norheim
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/5375679156#Organization/nasjonalt_kunnskapssenter_for_helsetjenesten> ; # Nasjonalt kunnskapssenter for helsetjenesten,
    schema:contributor <http://experiment.worldcat.org/entity/work/data/5375679156#Person/wisloff_torbjorn> ; # Torbjørn Wisløff
    schema:datePublished "2008" ;
    schema:description "Background Cardiovascular disease (CVD) has for decades been the most common cause of death in Norway and most other Western countries. Several groups of drugs have shown in clinical trials to prevent CVD. In this report, we have evaluated the cost-effectiveness of these drugs. Methods Based on a model of the progression of CVD from healthy to death, we explored which drugs that might be cost-effective. Analyses were conducted both compared to no treatment and between different drugs. Analyses were conducted on different risk levels and in different age groups for both men and women. We also performed probabilistic sensitivity analyses. Our analyses were accompanied by a systematic review of other economic evaluations of preventive strategies against CVD. Results Calcium channel blockers, thiazides, beta blockers, aspirin and statins were all cost-effective compared to no treatment for all groups of men and women in age groups between 40 and 69. The life year gains for each of the drugs varied between 3 and 17 months. Calcium channel blockers and thiazides were the most cost-effective combination of two antihypertensive drugs. In the base case analyses, the combination of calcium channel blockers, thiazides and ACE-inhibitors was the most cost-effective combination of three drugs. The sensitivity analyses indicate considerable uncertainty related to the question of which was the most cost-effective of the antihypertensive drugs. Whether treatment was cost-effective compared to no treatment was concerned with less uncertainty. Our systematic review of other economic evaluations showed considerable discrepancies between analyses of prevention strategies against CVD. Discussion The results of this study indicate that statins, several antihypertensives and aspirin are cost-effective in all analysed groups between 40 and 69 years old. It is worthwhile noting, however, that the model is built on numerous assumptions, and this introduces considerable uncertainty with respect to optimal choice of therapies."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/5375679156> ;
    schema:genre "Systematic Review"@en ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/5375679156#Series/online_access_ncbi_ncbi_bookshelf> ; # Online access: NCBI NCBI Bookshelf.
    schema:name "Health economic evaluation of primary prevention strategies against cardiovascular disease"@en ;
    schema:productID "1048107392" ;
    schema:url <https://www.ncbi.nlm.nih.gov/books/NBK464914> ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK464914/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1048107392> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/5375679156#CreativeWork/kostnader_og_levearsgevinster_ved_medikamentell_primaerforebygging_av_hjertekarsykdom> # Kostnader og leveårsgevinster ved medikamentell primærforebygging av hjertekarsykdom.
    a schema:CreativeWork ;
    schema:creator <http://experiment.worldcat.org/entity/work/data/5375679156#Person/wisloff_torbjorn> ; # Torbjørn Wisløff
    schema:name "Kostnader og leveårsgevinster ved medikamentell primærforebygging av hjertekarsykdom." ;
    .

<http://experiment.worldcat.org/entity/work/data/5375679156#Organization/nasjonalt_kunnskapssenter_for_helsetjenesten> # Nasjonalt kunnskapssenter for helsetjenesten,
    a schema:Organization ;
    schema:name "Nasjonalt kunnskapssenter for helsetjenesten," ;
    .

<http://experiment.worldcat.org/entity/work/data/5375679156#Person/halvorsen_sigrun> # Sigrun Halvorsen
    a schema:Person ;
    schema:familyName "Halvorsen" ;
    schema:givenName "Sigrun" ;
    schema:name "Sigrun Halvorsen" ;
    .

<http://experiment.worldcat.org/entity/work/data/5375679156#Person/kristiansen_ivar_sonbo_1947> # Ivar Sønbø Kristiansen
    a schema:Person ;
    schema:birthDate "1947" ;
    schema:familyName "Kristiansen" ;
    schema:givenName "Ivar Sønbø" ;
    schema:name "Ivar Sønbø Kristiansen" ;
    .

<http://experiment.worldcat.org/entity/work/data/5375679156#Person/norheim_ole_frithjof> # Ole Frithjof Norheim
    a schema:Person ;
    schema:familyName "Norheim" ;
    schema:givenName "Ole Frithjof" ;
    schema:name "Ole Frithjof Norheim" ;
    .

<http://experiment.worldcat.org/entity/work/data/5375679156#Person/selmer_randi> # Randi Selmer
    a schema:Person ;
    schema:familyName "Selmer" ;
    schema:givenName "Randi" ;
    schema:name "Randi Selmer" ;
    .

<http://experiment.worldcat.org/entity/work/data/5375679156#Person/wisloff_torbjorn> # Torbjørn Wisløff
    a schema:Person ;
    schema:familyName "Wisløff" ;
    schema:givenName "Torbjørn" ;
    schema:name "Torbjørn Wisløff" ;
    .

<http://experiment.worldcat.org/entity/work/data/5375679156#Series/online_access_ncbi_ncbi_bookshelf> # Online access: NCBI NCBI Bookshelf.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1048107392> ; # Health economic evaluation of primary prevention strategies against cardiovascular disease
    schema:name "Online access: NCBI NCBI Bookshelf." ;
    .

<http://experiment.worldcat.org/entity/work/data/5375679156#Topic/cardiovascular_agents_economics> # Cardiovascular Agents--economics
    a schema:Intangible ;
    schema:name "Cardiovascular Agents--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/5375679156#Topic/cardiovascular_agents_therapeutic_use> # Cardiovascular Agents--therapeutic use
    a schema:Intangible ;
    schema:name "Cardiovascular Agents--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/5375679156#Topic/cardiovascular_diseases_drug_therapy> # Cardiovascular Diseases--drug therapy
    a schema:Intangible ;
    schema:name "Cardiovascular Diseases--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/5375679156#Topic/cost_benefit_analysis> # Cost-Benefit Analysis
    a schema:Intangible ;
    schema:name "Cost-Benefit Analysis"@en ;
    .

<http://www.worldcat.org/title/-/oclc/1048107392>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/1048107392> ; # Health economic evaluation of primary prevention strategies against cardiovascular disease
    schema:dateModified "2019-10-11" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.